Vnitr Lek 2024, 70(1):28-34 | DOI: 10.36290/vnl.2024.005

The results of a survey: "Diagnosis and treatment of heart failure in the clinical practice"

Filip Málek1, Aleš Linhart2, Radek Pudil3, Jiří Veselý4, 5
1 Kardiovaskulární centrum, Nemocnice Na Homolce, Praha
2 II. interní klinika kardiologie a angiologie, VFN v Praze
3 I. interní kardioangiologická klinika, LF UK v Hradci Králové
4 Lékařská fakulta v Hradci Králové, Univerzita Karlova
5 Kardiologická ambulance Edumed s. r. o., Broumov

The survey from outpatients secondary care clinics was focused on questions related to diagnostics and treatment of heart failure. A special attention was paid to the presence of symptoms of patients not yet diagnosed with heart failure. The survey showed reserves in the heart failure treatment. It has been further shown, that the important proportion of patients have symptoms but are not properly diagnosed with heart failure, despite having elevated NT-proBNP levels.

Keywords: survey, heart failure, diagnosis, symptoms.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F, Linhart A, Pudil R, Veselý J. The results of a survey: "Diagnosis and treatment of heart failure in the clinical practice". Vnitr Lek. 2024;70(1):28-34. doi: 10.36290/vnl.2024.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. Go to original source... Go to PubMed...
    2. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J. 2023:OO;1-13. Go to original source...
    3. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7. PMID: 36356631. Go to original source... Go to PubMed...
    4. Savarese G, Kishi T, Vardeny O, et al. Heart Failure. Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 Jan;11(1):1-14. doi: 10.1016/j.jchf.2022.08.009. Epub 2022 Sep 7. Erratum in: JACC Heart Fail. 2023 Dec;11(12):1773. PMID: 36202739. Go to original source... Go to PubMed...
    5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021, doi: 10.1056/NEJMoa2107038. Go to original source... Go to PubMed...
    6. Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians and primary care physicians. Eur Heart J. 2008;29:1739-1754. Go to original source... Go to PubMed...
    7. Maggioni AP, Dahlstrom U, Filippatos G, et al. Heart Failure Association of the European Society of C. EURObservational Research Programme: regional differences and 1-year follow-up resultsof theHeartFailurePilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808-817. Go to original source... Go to PubMed...
    8. Howlett J, Comin-Colet J, Dickstein K, et al. Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. ESC Heart Failure. 2018,5:172-183. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.